Logo image of RSLS

RESHAPE LIFESCIENCES INC (RSLS) Stock Price, Quote, News and Overview

NASDAQ:RSLS - Nasdaq - US76090R3093 - Common Stock - Currency: USD

0.3631  -0.02 (-4.45%)

Premarket: 0.3573 -0.01 (-1.6%)

RSLS Quote, Performance and Key Statistics

RESHAPE LIFESCIENCES INC

NASDAQ:RSLS (4/16/2025, 8:00:01 PM)

Premarket: 0.3573 -0.01 (-1.6%)

0.3631

-0.02 (-4.45%)

Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
Statistics
52 Week High29
52 Week Low0.3
Market Cap4.10M
Shares11.28M
Float10.81M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-13 2025-05-13
IPO10-06 2016-10-06


RSLS short term performance overview.The bars show the price performance of RSLS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40 -60 -80

RSLS long term performance overview.The bars show the price performance of RSLS in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of RSLS is 0.3631 USD. In the past month the price decreased by -42.37%. In the past year, price decreased by -96.21%.

RESHAPE LIFESCIENCES INC / RSLS Daily stock chart

RSLS Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 27.13 224.94B
ISRG INTUITIVE SURGICAL INC 65.67 172.45B
BSX BOSTON SCIENTIFIC CORP 37.95 140.88B
SYK STRYKER CORP 28.44 132.32B
MDT MEDTRONIC PLC 15.49 106.07B
BDX BECTON DICKINSON AND CO 14.41 57.54B
EW EDWARDS LIFESCIENCES CORP 27.18 41.86B
IDXX IDEXX LABORATORIES INC 35.77 32.61B
RMD RESMED INC 23.92 31.06B
GEHC GE HEALTHCARE TECHNOLOGY 13.69 28.11B
DXCM DEXCOM INC 41.65 26.95B
PHG KONINKLIJKE PHILIPS NVR- NY 15.11 22.30B

About RSLS

Company Profile

RSLS logo image ReShape Lifesciences, Inc. is a medical device company, which focuses on technology to treat obesity and metabolic diseases. The company is headquartered in San Clemente, California and currently employs 31 full-time employees. The company went IPO on 2016-10-06. The firm offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.

Company Info

RESHAPE LIFESCIENCES INC

1001 Calle Amanecer

San Clemente CALIFORNIA 92673 US

CEO: Andrew Rasdal

Employees: 29

Company Website: https://www.reshapelifesciences.com/obalon/

Investor Relations: https://ir.reshapelifesciences.com/

Phone: 19494296680

RESHAPE LIFESCIENCES INC / RSLS FAQ

What is the stock price of RESHAPE LIFESCIENCES INC today?

The current stock price of RSLS is 0.3631 USD. The price decreased by -4.45% in the last trading session.


What is the ticker symbol for RESHAPE LIFESCIENCES INC stock?

The exchange symbol of RESHAPE LIFESCIENCES INC is RSLS and it is listed on the Nasdaq exchange.


On which exchange is RSLS stock listed?

RSLS stock is listed on the Nasdaq exchange.


What is RESHAPE LIFESCIENCES INC worth?

RESHAPE LIFESCIENCES INC (RSLS) has a market capitalization of 4.10M USD. This makes RSLS a Nano Cap stock.


How many employees does RESHAPE LIFESCIENCES INC have?

RESHAPE LIFESCIENCES INC (RSLS) currently has 29 employees.


Is RESHAPE LIFESCIENCES INC (RSLS) expected to grow?

The Revenue of RESHAPE LIFESCIENCES INC (RSLS) is expected to grow by 12.24% in the next year. Check the estimates tab for more information on the RSLS EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy RESHAPE LIFESCIENCES INC (RSLS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does RESHAPE LIFESCIENCES INC (RSLS) stock pay dividends?

RSLS does not pay a dividend.


When does RESHAPE LIFESCIENCES INC (RSLS) report earnings?

RESHAPE LIFESCIENCES INC (RSLS) will report earnings on 2025-05-13.


What is the Price/Earnings (PE) ratio of RESHAPE LIFESCIENCES INC (RSLS)?

RESHAPE LIFESCIENCES INC (RSLS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-205.92).


What is the Short Interest ratio of RESHAPE LIFESCIENCES INC (RSLS) stock?

The outstanding short interest for RESHAPE LIFESCIENCES INC (RSLS) is 16.61% of its float. Check the ownership tab for more information on the RSLS short interest.


RSLS Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

RSLS Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to RSLS. The financial health of RSLS is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

RSLS Financial Highlights

Over the last trailing twelve months RSLS reported a non-GAAP Earnings per Share(EPS) of -205.92. The EPS increased by 95.65% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -125.86%
ROE -475.25%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-204.61%
Sales Q2Q%6.36%
EPS 1Y (TTM)95.65%
Revenue 1Y (TTM)-16.59%

RSLS Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 43% to RSLS. The Buy consensus is the average rating of analysts ratings from 6 analysts.

For the next year, analysts expect an EPS growth of 99.78% and a revenue growth 12.24% for RSLS


Ownership
Inst Owners4.1%
Ins Owners5.18%
Short Float %16.61%
Short Ratio0.35
Analysts
Analysts43.33
Price TargetN/A
EPS Next Y99.78%
Revenue Next Year12.24%